Elena Munez and Jesus Sierra.
That way, according to Munez, “indications” of these antivirals would be allowed, but “Including data to be able to analyze results and build evidence about“Thus eliminating the difficulty they present today with regard to administrative procedures. A difficulty that extends from health centers to hospitals, where” Barriers to the administration of antivirals in covid patients, mainly monoclonal antibodies“, as Munez explains.
For internists, this condition occurs because “the monoclonal antibodies undergoes the first indication screening, which must be reviewed expert committee And, finally, make a decision”. Similarly, Munez says the decision varies greatly because, on occasions, it happens that “a professional is not convinced of the indication for monoclonal antibodies in these patients and then Also, the committee approves it. , Or, conversely, as the case may be, the committee gives its indication and does not approve of its administration”.
In this sense, Munez explains that ” monoclonal antibodiesbeing from intravenous administration And this a. acts like SARS-CoV-2 . direct antiviral againstThey have some restrictions. A condition that does not occur with “remdesivir and, in the case of paxlovid, still very rarely”.
“The bureaucratic problems that professionals face when prescribing COVID antivirals depend on the type of antiviral that is used”
For the specialist, in general, “bureaucratic problems that occur when prescribing professionals” covid antiviral Depends on the type of antiviral used and the particular state of activity. an opinion that is also shared jesus sierraHead of the Hospital Pharmacy Section of the Hospital de Jerez and spokesperson for the Spanish Society of Hospital Pharmacy (SEFH), who gives assurance medical writing That “there are two great difficulties”.
On the one hand, the constraint “from an interaction standpoint, as in the case of paxlovid, for which a very high proportion of patients preclude its use due to the concomitant use of ‘ritonavir’, a antiretrovirals Incompatible with multiple treatments of patients.
and, on the other hand, “for patients who cannot be treated” paxlovidIt is recommended to be treated with remdesivir, For which there is a logistic problem. Apart from the fact that it is intravenous, it is administered to a non-hospitalized patient for three days, due to which this person goes to the hospital in that period.”
How do these problems affect the health of the patient?
Sierra also explains how this difficulty with treating healthcare professionals. covid antiviral, And, in this sense, he underlines that “this is a population that has a high risk of remission for severe covid. However, it should be kept in mind that, according to studies, the proportion of patients with severe covid is less than seven.” Up to 14 per cent compared to 80 per cent who do not return with this pathology. “Not much” difference in patients with severe covid.
Instead, according to Sierra, this data “uninfected patients“, therefore it will be necessary to first study the “protective potential of vaccines in these patients”, as “it has already been observed that the vaccine protects against progression of a more serious disease but not infection”. And, once it “There should be an antiviral characterization for this type of patient”, they concluded.
While it may include statements, data or notes from health institutions or professionals, the information contained in medical writing is edited and prepared by journalists. We advise the reader to consult a health professional on any health-related questions.